Humacyte, Inc. (HUMA)
NASDAQ
Key stats Fiscal year 2025
Income statement
- Revenue
- 2,038,000
- Net income
- -40,833,000
- Operating income
- -108,137,000
- Earnings per share
- -0.26
- R&D expense
- 69,302,000
Growth and profitability
- Operating margin
- -5,306.04
- Net margin
- -2,003.58
- Return on equity
- -1,313.38
- Return on assets
- -35.09
- Free cash flow margin
- -5,197.55
Balance sheet
- Total assets
- 116,366,000
- Total liabilities
- 113,257,000
- Shareholders' equity
- 3,109,000
- Cash and equivalents
- 50,497,000
- Debt
- 35,444,000
- Net debt
- -15,053,000
- Current ratio
- 3.69
- Debt to equity
- 11.40
Cash flow and ratios
- Operating cash flow
- -105,042,000
- Free cash flow
- -105,926,000
Shareholder returns
- Shares outstanding
- 277,798,105
- Book value per share
- 0.01
Company information
- Headquarters
- Durham, NC
- Exchange
- NASDAQ
- Fiscal year end
- 12-31
- Industry (SEC)
- Biological Products, (no Diagnostic Substances)
Fiscal year end: · Source: SEC EDGAR
Humacyte, Inc. trades on NASDAQ under the ticker symbol HUMA. This page brings together its price chart, company profile, key financial figures and technical indicators.